Table 5 Group 4: Immunohistochemical expression of TOPK (patchy or diffuse) and clinicopathological and molecular features in metastatic colorectal cancer patients treated with anti-EGFR therapy
N (%) | |||
|---|---|---|---|
Clinicopathological features | Patchy | Diffuse | P -value |
Age (years) | |||
Mean, range | 65.7, 48–82 | 60.7, 26–79 | 0.113 |
Gender | |||
Female | 8 (36.4) | 9 (39.1) | 0.848 |
Male | 14 (63.6) | 14 (60.9) | |
Clinical response | |||
Progressive disease | 13 (59.1) | 10 (43.5) | 0.528 |
Partial response | 4 (18.2) | 7 (30.4) | |
Stable disease | 5 (22.7) | 6 (26.1) | |
KRAS codon 12 and 13 | |||
Wild type | 13 (59.1) | 19 (82.6) | 0.082 |
Mutation | 9 (40.9) | 4 (17.4) | |
BRAF codon 600 | |||
Wild type | 20 (90.9) | 21 (91.3) | 1.0 |
Mutation | 2 (9.1) | 2 (8.7) | |
KRAS/BRAF | |||
Both wild type | 11 (50.0) | 17 (73.9) | 0.098 |
KRAS or BRAF mutation | 11 (50.0) | 6 (26.1) | |
Microsatellite status | |||
Stable/low | 22 (100.0) | 22 (100.0) | |
High | |||
EGFR amplification | |||
No copy number gain | 4 (19.1) | 3 (13.0) | 0.693 |
Copy number gain | 17 (81.0) | 20 (87.0) | |
PI3KCA | |||
Loss | 19 (86.4) | 20 (87.0) | 1.0 |
Overexpression | 3 (13.6) | 3 (13.0) | |
PTEN | |||
Loss | 11 (50.0) | 6 (26.1) | 0.09 |
Overexpression | 11 (50.0) | 17 (73.9) | |
Rate (95% CI) | |||
5-year survival time | |||
All patients | 34.5 (11–60) | 13.5 (1–40) | 0.473 |
Either KRAS or BRAF mutation | 18.2 (3–44) | 16.7 (0–51) | 0.887 |
Both wild type KRAS and BRAF | 66.7 (5–95) | 15.3 (1–45) | 0.018 |
Stable disease or response | 100 | 31.3 (8–59) | 0.01 |
